Medline Inc.

MDLN Healthcare Medical Instruments & Supplies

Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024.

Revenue
+14.1%
Free cash flow
+916.1%
Total debt
−23.7%

Quarter to September 2026, against a year earlier

39.96 0.39 −0.97%
Market cap
$52.3B
P/E
58.4×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
2.25
Beneish M
−2.38
Dividend safety
n/a

Medline Inc. 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 26, 2026 · Filed · accepted 4:32 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2026: 26 added · 5 removed · 44 modified; 28 with only figures updated

  1. Modified

    This Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to help you understand the financial condition, results of operations, and present business of Medline and Medline Holdings (f/k/a, Mozart Holdings, LP, the predecessor of Medline). This MD&A should be read in conjunction with our consolidated financial statements and the accompanying notes in Part I, “Item 1—Financial Statements” of this Quarterly Report and in Part II, “Item 8—Financial Statements and SupplementalSupplementary Data” of our 2025 Form 10-K, as well as the correspondingand MD&A contained in our 2025 Form 10-K. Some of the information included in this MD&A or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, include forward-looking statements that involve risks and uncertainties. Our future results and financial condition may differ materially from those we currently anticipate. You should review the “Cautionary Note Regarding Forward-Looking Statements” section in this Quarterly Report and Part I, “Item 1A—Risk Factors” of our 2025 Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. For purposes of the MD&A, references to the “Company,” “Medline,” “we,” “us,” and “our” mean Medline Inc. and its consolidated subsidiaries.

74 more changes in this Item, word by word, in Powerpack.